Koumas Christoforos, Laibangyang Anya, Barron Shanna L, Mittler Mark A, Schneider Steven J, Rodgers Shaun D
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
Division of Pediatric Neurosurgery, Cohen Children's Medical Center, 410 Lakeville Road, Suite 204, New Hyde Park, NY, 11042, USA.
Childs Nerv Syst. 2019 Nov;35(11):2099-2105. doi: 10.1007/s00381-019-04258-1. Epub 2019 Jun 18.
The endoscopic endonasal approach (EEA) is a credible surgical alternative for the resection of sellar and suprasellar lesions such as pituitary adenomas, craniopharyngiomas, and Rathke cleft cysts. However, its application to pediatric patients poses several unique challenges that have not yet been well evaluated. The authors evaluate the safety, efficacy, and outcomes associated with the use of the EEA for treatment of these pathologic entities in pediatric patients.
Retrospective review of 30 patients between the ages of two and 24 who underwent endoscopic endonasal resection of sellar or suprasellar lesions between January 2010 and December 2015. Endocrinological and ophthalmological outcomes, as well as extent of resection and complications were all evaluated.
Gross total resection was achieved in eight of the nine pituitary adenomas, nine of the 12 craniopharyngiomas, and six of the nine Rathke cleft cysts. Of the 30 patients, 22 remained disease free at last follow-up. A total of six patients developed hypopituitarism and five developed diabetes insipidus. Eleven patients experienced improved vision, sixteen experienced no change, and one patient experienced visual worsening. Postoperative cerebrospinal fluid leak was seen in a single case and later resolved, vasospasm/stroke was experienced by 10% of patients, and new obesity was recorded in 10% of patients. There were no perioperative deaths.
Endoscopic endonasal resection is a safe and effective surgical alternative for the management of sellar and suprasellar pathologies in pediatric populations with excellent outcomes, minimal complications, and a low risk of morbidity.
鼻内镜经鼻入路(EEA)是切除鞍区和鞍上病变(如垂体腺瘤、颅咽管瘤和拉克氏囊肿)的一种可靠的手术替代方法。然而,将其应用于儿科患者带来了一些尚未得到充分评估的独特挑战。作者评估了使用EEA治疗儿科患者这些病理实体的安全性、有效性和结果。
回顾性分析2010年1月至2015年12月期间30例年龄在2岁至24岁之间接受鼻内镜经鼻切除鞍区或鞍上病变的患者。评估内分泌和眼科结果,以及切除范围和并发症。
9例垂体腺瘤中有8例实现了全切,12例颅咽管瘤中有9例,9例拉克氏囊肿中有6例。30例患者中,22例在最后一次随访时无疾病复发。共有6例患者发生垂体功能减退,5例发生尿崩症。11例患者视力改善,16例无变化,1例患者视力恶化。术后脑脊液漏1例,后来自行缓解,10%的患者发生血管痉挛/中风,10%的患者出现新发肥胖。无围手术期死亡病例。
鼻内镜经鼻切除术是治疗儿科患者鞍区和鞍上病变的一种安全有效的手术替代方法,效果良好,并发症少,发病风险低。